Immatics Biotechnologies has appointed Peter Chambré as chairman of the board to replace Thomas Widmann, who steps down after eight years in the post.
Chambré holds several chairman positions in the life sciences industry and previously served as CEO of Cambridge Antibody Technology from 2002 until its acquisition by AstraZeneca in 2006.
Paul Higham, CEO of Immatics, said: “I am delighted to welcome Peter as our new chairman. We are approaching a crucial period at Immatics, and Peter’s experience and track record in successfully developing biopharmaceutical companies will be invaluable, as we seek to produce a step-change in the treatment of cancer and maximise returns to our investors.”
Chambré joins Tuebingen-based Immatics following the German biotech’s recent completion of phase III patient enrollment for a trial of its therapeutic vaccine for renal cancer IMA901.
He said: “Immatics’ vaccines, based on the company’s highly rational approach to cancer vaccine discovery, have already demonstrated very promising results in clinical trials.
“With IMA901, Immatics’ lead multi-peptide based vaccine now in phase III development for renal cancer, and a number of other projects in clinical development, this is an extremely exciting company.”